İlKer Kurt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
İlKer Kurt has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Birsel Sönmez Uydeş Doğan
Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye
4 shared publications - Esen Gül Koçak
Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye
3 shared publications - Zeliha Pala Kara
Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye
3 shared publications - Begüm Sanat Demir
Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye
2 shared publications - Bilgul Mete
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
2 shared publications - Fehmi Tabak
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Drug-related problems, adherence and quality of life in outpatients receiving endocrine treatment for hormone receptor-positive breast cancer: A prospective study
Introduction: Patients receiving long-term endocrine treatment (ET) for hormone receptor-positive breast cancer commonly use supportive-care and concomitant medicines, resulting in complex regimens with greater risks of drug-related problems (DRPs) and non-adherence. This study quantified DRPs per patient and assessed their management, potential drug–drug interactions, ET adherence, and within-patient quality-of-life (QoL) changes. Methods: This prospective, single-centre, single-arm pre–post study included 95 outpatients receiving ET. A clinical pharmacist reviewed medication regimens, classifying DRPs and interventions with Pharmaceutical Care Network Europe V9.0. Assessments included Micromedex screening for potential interactions, the 8-item Morisky Medication Adherence Scale for adherence, and the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 for QoL at baseline and 2 months. Results: Overall, 287 DRPs were identified in 88 patients (92.6%; 3.02 ± 1.77 per patient): 15 (5.2%) involved ET, 118 (41.1%) supportive-care medicines, and 154 (53.7%) other concomitant medicines. Of 688 interventions, 686 (99.7%) were accepted, while 142 DRPs (49.5%) were completely resolved. Potential interactions were detected in 54 patients (56.8%); 54/110 (49.1%) were major. Low ET adherence was identified in 50/93 patients (53.8%). Among 85 patients with paired QoL data, global health/QoL and functional scores increased significantly. Higher DRP counts correlated with poorer QoL, whereas higher adherence correlated with lower symptom burden. Conclusions: DRPs extended beyond ET to patients’ complete medication regimens. Despite high intervention acceptance, complete resolution was less frequent. Controlled multicentre studies with longer follow-up are needed to evaluate the effects of clinical pharmacist-led care on DRP resolution, ET adherence, and QoL.
- 8 October 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Open AccessDrug-related problems, adherence and quality of life in outpatients receiving endocrine treatment for hormone receptor-positive breast cancer: A prospective study
Introduction: Patients receiving long-term endocrine treatment (ET) for hormone receptor-positive breast cancer commonly use supportive-care and concomitant medicines, resulting in complex regimens with greater risks of drug-related problems (DRPs) and non-adherence. This study quantified DRPs per patient and assessed their management, potential drug–drug interactions, ET adherence, and within-patient quality-of-life (QoL) changes. Methods: This prospective, single-centre, single-arm pre–post study included 95 outpatients receiving ET. A clinical pharmacist reviewed medication regimens, classifying DRPs and interventions with Pharmaceutical Care Network Europe V9.0. Assessments included Micromedex screening for potential interactions, the 8-item Morisky Medication Adherence Scale for adherence, and the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 for QoL at baseline and 2 months. Results: Overall, 287 DRPs were identified in 88 patients (92.6%; 3.02 ± 1.77 per patient): 15 (5.2%) involved ET, 118 (41.1%) supportive-care medicines, and 154 (53.7%) other concomitant medicines. Of 688 interventions, 686 (99.7%) were accepted, while 142 DRPs (49.5%) were completely resolved. Potential interactions were detected in 54 patients (56.8%); 54/110 (49.1%) were major. Low ET adherence was identified in 50/93 patients (53.8%). Among 85 patients with paired QoL data, global health/QoL and functional scores increased significantly. Higher DRP counts correlated with poorer QoL, whereas higher adherence correlated with lower symptom burden. Conclusions: DRPs extended beyond ET to patients’ complete medication regimens. Despite high intervention acceptance, complete resolution was less frequent. Controlled multicentre studies with longer follow-up are needed to evaluate the effects of clinical pharmacist-led care on DRP resolution, ET adherence, and QoL.
- 22 August 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 5241-5250
Evaluation of the Associations Between Medication Adherence, Polypharmacy, and Health-Related Quality of Life in People Living with HIV: A Cross-Sectional Study
- 22 August 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 5241-5250
Evaluation of the Associations Between Medication Adherence, Polypharmacy, and Health-Related Quality of Life in People Living with HIV: A Cross-Sectional Study
- Open Access
- 18 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 178
Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study
Purpose: Vancomycin therapeutic drug monitoring is essential for optimizing efficacy and reducing the risk of vancomycin-associated acute kidney injury (VA-AKI). Although recent guidelines recommend the ratio of area under the curve over 24 h to minimum inhibitory concentration (AUC 24 /MIC)–based monitoring over trough concentration-based monitoring, differences between AUC 24 /MIC estimation methods (e.g., pharmacokinetic equations and Bayesian approaches) may influence therapeutic classification in clinical practice. In addition, pharmacogenetic factors contributing to interindividual variability in vancomycin exposure remain incompletely characterized. Methods: This prospective, single-center cohort study included adult patients who received intravenous vancomycin for at least 72 h between June 2024 and April 2025. Vancomycin trough and peak plasma concentrations were measured using an enzyme-linked immunosorbent assay. AUC 24 /MIC values were calculated using pharmacokinetic equation and Bayesian method. Agreement in therapeutic classification between trough concentration–based and AUC 24 /MIC-based monitoring was assessed. Associations between the rs2789047 genetic variant and relevant parameters were also evaluated. Results: Thirty-six patients were included, of whom 38.9% developed VA-AKI. Despite strong correlations between trough concentration and AUC 24 /MIC values ( r = 0.84–0.87), substantial discordance in therapeutic classification was observed, with agreement rates of 63.9% for pharmacokinetic equation-based and 66.7% for Bayesian-based compared with trough concentration-based monitoring. In contrast, pharmacokinetic equation-based and Bayesian-based methods demonstrated strong concordance (86.1%). Higher trough concentrations and AUC 24 /MIC values were significantly associated with VA-AKI ( p < 0.001). Carriers of rs2789047 A-allele exhibited higher trough concentrations and reduced elimination rates. Conclusion: Trough concentration-based monitoring frequently misclassified vancomycin exposure compared with AUC 24 /MIC–based approaches. Pharmacogenetic variability may further influence vancomycin exposure.
- 18 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 178
Open AccessEvaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study
Purpose: Vancomycin therapeutic drug monitoring is essential for optimizing efficacy and reducing the risk of vancomycin-associated acute kidney injury (VA-AKI). Although recent guidelines recommend the ratio of area under the curve over 24 h to minimum inhibitory concentration (AUC 24 /MIC)–based monitoring over trough concentration-based monitoring, differences between AUC 24 /MIC estimation methods (e.g., pharmacokinetic equations and Bayesian approaches) may influence therapeutic classification in clinical practice. In addition, pharmacogenetic factors contributing to interindividual variability in vancomycin exposure remain incompletely characterized. Methods: This prospective, single-center cohort study included adult patients who received intravenous vancomycin for at least 72 h between June 2024 and April 2025. Vancomycin trough and peak plasma concentrations were measured using an enzyme-linked immunosorbent assay. AUC 24 /MIC values were calculated using pharmacokinetic equation and Bayesian method. Agreement in therapeutic classification between trough concentration–based and AUC 24 /MIC-based monitoring was assessed. Associations between the rs2789047 genetic variant and relevant parameters were also evaluated. Results: Thirty-six patients were included, of whom 38.9% developed VA-AKI. Despite strong correlations between trough concentration and AUC 24 /MIC values ( r = 0.84–0.87), substantial discordance in therapeutic classification was observed, with agreement rates of 63.9% for pharmacokinetic equation-based and 66.7% for Bayesian-based compared with trough concentration-based monitoring. In contrast, pharmacokinetic equation-based and Bayesian-based methods demonstrated strong concordance (86.1%). Higher trough concentrations and AUC 24 /MIC values were significantly associated with VA-AKI ( p < 0.001). Carriers of rs2789047 A-allele exhibited higher trough concentrations and reduced elimination rates. Conclusion: Trough concentration-based monitoring frequently misclassified vancomycin exposure compared with AUC 24 /MIC–based approaches. Pharmacogenetic variability may further influence vancomycin exposure.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 27-35
Evaluation of Drug-Related Problems in Inpatients at the Neurology Department of Tertiary University Hospital in Türkiye
Background and Aims: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in inpatients in the neurology department in Türkiye remain unknown. This study aimed to determine the characteristics of DRPs and to identify drug-drug interactions (DDIs) in the neurology department of a tertiary university hospital in Türkiye.Methods: This prospective study with clinical pharmacist (CP) intervention was conducted at the Department of Neurology, Istanbul University Istanbul Faculty of Medicine Hospital, between December 2023 and June 2024 by clinical pharmacy residents (CPRs). The characteristics of DRPs were categorised using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.1, and DDIs were identified using Micromedex® drug interaction software.Results: A total of 106 DRPs were detected in 63 inpatients, an average of 1.68 DRPs per patient. Using the PCNE classification system, treatment safety (P2) was identified as the most common type of DRP (69; 65.09%), whereas drug selection (C1) was the primary cause (94; 83.93%). CPRs provided a total of 120 interventions, and most interventions occurred at the prescriber level (I1) (107; 89.17%), and all were accepted. A total of 205 DDIs were detected (59/63;93.65%), most of which were classified as major (136;66.34%).Conclusions: This study demonstrates that DRPs can occur at any stage of the prescribing process and are common among inpatients in the neurology department in Türkiye. These findings may encourage further research on the roles of CPs in neurology departments using controlled study designs.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 27-35
Evaluation of Drug-Related Problems in Inpatients at the Neurology Department of Tertiary University Hospital in Türkiye
Background and Aims: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in inpatients in the neurology department in Türkiye remain unknown. This study aimed to determine the characteristics of DRPs and to identify drug-drug interactions (DDIs) in the neurology department of a tertiary university hospital in Türkiye.Methods: This prospective study with clinical pharmacist (CP) intervention was conducted at the Department of Neurology, Istanbul University Istanbul Faculty of Medicine Hospital, between December 2023 and June 2024 by clinical pharmacy residents (CPRs). The characteristics of DRPs were categorised using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.1, and DDIs were identified using Micromedex® drug interaction software.Results: A total of 106 DRPs were detected in 63 inpatients, an average of 1.68 DRPs per patient. Using the PCNE classification system, treatment safety (P2) was identified as the most common type of DRP (69; 65.09%), whereas drug selection (C1) was the primary cause (94; 83.93%). CPRs provided a total of 120 interventions, and most interventions occurred at the prescriber level (I1) (107; 89.17%), and all were accepted. A total of 205 DDIs were detected (59/63;93.65%), most of which were classified as major (136;66.34%).Conclusions: This study demonstrates that DRPs can occur at any stage of the prescribing process and are common among inpatients in the neurology department in Türkiye. These findings may encourage further research on the roles of CPs in neurology departments using controlled study designs.